Aptuit To Expand API Capacity Due To Increased Demand For Integrated Development

– Opens 1600L/1000L reactor stream at Oxford, UK and increases API capacity at Verona, Italy

GREENWICH, Conn., April 3, 2015 /PRNewswire/ — Dr. Jonathan Goldman, CEO, Aptuit LLC, announced that Aptuit has increased its global capacity for Active Pharmaceutical Ingredient (API) Manufacture due to increased demand for API, and for its integrated and comprehensive candidate-to-IND development solution.

Dr. Goldman stated, “Customer demand for our high quality, integrated, fully inclusive candidate-to-IND solutions has increased over 300% on an annual basis. As part of our strategy of investing in our infrastructure, we therefore have opened a 1600L/1000L reactor stream at our internationally renowned API facility in Oxford, UK and increased throughput at our 400L reactors at our world-class, fully integrated, former large Pharma R&D center of excellence in Verona, Italy.

Dr. Goldman explained that Aptuit’s strategy will allow increased throughput of integrated development programs, as well as deliver standalone API at 40-120 kg batch scale for early to mid-stage clinical trials. “There is a gap in the market for high quality API at this scale, and Aptuit is delighted to serve this need.”

“As recognized by our recent 2015 Life Science Leader CMO Leadership Award for Quality, our company differentiates in API by quality, best-in-class science, and delivery of complex chemistry solutions. Our ability to combine this with drug product and analytical services results in unique integrated offerings in both CMC and complete IND enabling solutions. The innovative approach has created strong demand amongst customers, and stimulated our plan to re-invest to increase our capacity in API.

Dr. Goldman concluded, “Our mission is to help discover and develop new medicines with outstanding quality and world class scientific problem solving. Aptuit is committed to being the best-in-class provider of fully integrated drug discovery and development services, supported by a culture of scientific excellence and innovation.”

Aptuit LLC provides the most complete set of integrated early discovery to mid-phase drug development services in the pharmaceutical industry including Drug Design & Discovery, API Development and Manufacture, Solid State Chemistry, CMC, Preclinical and IND enabling GLP/GMP programs. Fully integrated drug discovery & development services are available from a single site at The Aptuit Center for Drug Discovery & Development center in Verona, Italy. The company maintains resources around the world, with facilities in the US, UK and Italy. Aptuit LLC is partnered with Welsh, Carson, and Anderson & Stowe, one of the world’s leading private equity investors.

For more information about Aptuit, visit www.aptuit.com

CONTACT: Nerina Coppini, nerina.coppini@aptuit.com

New United Family Healthcare Hospital Unveiled in Qingdao, U.S. Ambassador in Attendance

QINGDAO, China, April 2, 2015 /PRNewswire/ — United Family Healthcare (“UFH”) welcomed U.S. Ambassador Max Baucus and Vice Mayor of Qingdao Ms. Luan Xin as they attended the inauguration of the organization’s newest international-standard facility in China, Qingdao United Family Hospital (“QDU”). Ambassador Baucus and Vice Mayor Luan together participated in a ribbon-cutting ceremony, joining United Family Healthcare Board Chair Ms. Roberta Lipson in delivering speeches on healthcare and partnership between their two nations.

Ceremonial ribbon cutting at Qingdao United Family Hospital’s inauguration. (from left to right, Qingdao United Family Hospital GM Rex Hancock, United Family Healthcare Senior Vice President for Medical Affairs David Rutstein, UFH Board Chair Roberta Lipson, U.S. Ambassador Max Baucus, and Qingdao Vice Mayor Luan Xin)

Ceremonial ribbon cutting at Qingdao United Family Hospital’s inauguration. (from left to right, Qingdao United Family Hospital GM Rex Hancock, United Family Healthcare Senior Vice President for Medical Affairs David Rutstein, UFH Board Chair Roberta Lipson, U.S. Ambassador Max Baucus, and Qingdao Vice Mayor Luan Xin)

Ms. Lipson echoed U.S. Ambassador Baucus and Vice Mayor Luan’s comments, stating, “We are proud to be opening Qingdao United Family Hospital, which specializes in comprehensive, world-class, personalized healthcare for the people of Qingdao. It is a shining example of the benefits to be gained for all by integrating best practices in Western and Chinese healthcare. We are looking forward to rolling out more cooperative projects like this in the future.”

With the rapid pace of Qingdao’s economic and social development, building an international business environment has become increasingly important for the port city’s future. The founding and operation of QDU will not only help to enhance the overall competitiveness and regional influence of the city, but also introduce international-standard healthcare to Qingdao. As healthcare resources are set to diversify, the Qingdao Laoshan District Health Board has expressed interest in opening a project exploring the new patient-centered, private international healthcare model offered by QDU and UFH.

With a total construction area of 30,000 square meters, QDU is a facility that offers multidisciplinary care and represents an significant multimillion US dollar investment for UFH. As a full-service hospital, residents of Qingdao and the greater Shandong area will benefit from UFH’s premium outpatient and inpatient medical services.

A tour of Qingdao United Family Hospital’s international-standard facilities. (Given by United Family Healthcare Board Chair Roberta Lipson (right) to U.S. Ambassador Max Baucus (left) and Qingdao Vice Mayor Luan Xin (center))

A tour of Qingdao United Family Hospital’s international-standard facilities. (Given by United Family Healthcare Board Chair Roberta Lipson (right) to U.S. Ambassador Max Baucus (left) and Qingdao Vice Mayor Luan Xin (center))

About Qingdao United Family Hospital (QDU)

The newly-unveiled Qingdao United Family Hospital, a full-service facility in the city's scenic Laoshan District. The hospital offers comprehensive, international-standard healthcare.

The newly-unveiled Qingdao United Family Hospital, a full-service facility in the city’s scenic Laoshan District. The hospital offers comprehensive, international-standard healthcare.

Located in the scenic Shilaoren Community of Laoshan District, just 30 minutes from the heart of downtown, UFH’s newest hospital will offer patients not only premium healthcare but also a beautiful environment in which to heal.

After opening, the hospital will begin with a beautiful 20,000 square meter facility, delivering comprehensive international-standard healthcare including Family Medicine, Internal Medicine, Surgery, Obstetrics and Gynecology, Pediatrics, Eye Clinic, and ENT services, as well as other specialties. QDU is staffed by an international team of physicians who will serve the city’s multinational patients with experience, compassion, and dedication.

QDU’s Hospital’s mission is to provide high-quality medical and healthcare services to the expatriate and Chinese populations throughout Qingdao and Shandong province. The hospital will combine UFH’s unique service model of international healthcare management with advanced medical equipment and technology to promote the development of the Chinese medical industry. QDU will also conduct academic exchanges focusing on international standards for diagnosis, treatment, and management, to lay the foundation for international cooperation in healthcare.

In addition, UFH has signed direct billing agreements with a number of major insurance providers, helping patients to settle claims directly with their providers. For more information, or to make an appointment at QDU, please call their 24hr Service Center at 4008-919191.

About United Family Healthcare (UFH)

United Family Healthcare (UFH), the healthcare services division of Chindex International, Inc., is a pioneering, international-standard healthcare organization in Asia whose mission is to provide comprehensive, integrated healthcare services in a uniquely warm and caring patient and family service-oriented environment.

After 18 years in China, UFH has established itself in Beijing, Shanghai, Guangzhou, Wuxi, Tianjin, Mongolia, and now Qingdao as the provider of choice for those who want the very best in personalized healthcare. UFH constantly strives for quality, safety, and service excellence. In China, all facilities in its system with long-term operation are accredited with the gold standard for quality by Joint Commission International (JCI). More information is available at http://www.ufh.com.cn.

Qingdao United Family Hospital Contact Information and Location

Qingdao United Family Hospital (QDU)
Shilaoren Community, 319 Hong Kong East Road,
Laoshan District, Qingdao
Urgent Care Hotline: (0532) 8163 3120
24hr Service Center: 4008-919191
http://qingdao.ufh.com.cn

Photo – http://photos.prnasia.com/prnh/20150402/0861502574-a
Photo – http://photos.prnasia.com/prnh/20150402/0861502574-b
Photo – http://photos.prnasia.com/prnh/20150402/0861502574-c

Ergomed Strengthens Presence in Asia to Meet Increasing Demand for Drug Development Services

Opens new office in Taiwan

LONDON, March 24, 2015 /PRNewswire/ — Ergomed plc, (LSE: ERGO or ‘Ergomed’) a profitable UK-based company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announced the opening of a new office in Taiwan. This expansion strengthens Ergomed’s clinical research and consultancy presence in Asia, and is a key element of the company’s strategic growth plan set out at the IPO.

This is Ergomed’s first office in Asia. The Company has decided to invest in organic growth as a first step. The new subsidiary company in Taipei will act as a hub for business activity across the country and the wider Asian market, ensuring Ergomed is best placed to support existing and new clients working in the region.

Miroslav Reljanovic, Chief Executive Officer of Ergomed plc commented: “We are very pleased to open an office in Taiwan where there is an expanding life science market. The Taiwan operations are in line with our strategy to expand in Asia through organic growth and acquisitions as stated at our IPO. We are currently working with some exciting Taiwanese companies and the new office gives us the platform to offer our services to pharma and biotech companies in the entire region. It is important for our clients in Taiwan to have local on-the-ground support integrated with an international drug development capability, and we can now provide that very effectively through our Taipei office.”

The Taiwan operations will be led by the new Executive Director of Global Clinical Operations, Dr Sy-Shi Wang who joined Ergomed in 2014. Dr Wang brings extensive international experience including Asia. She has worked previously at global US biotechnology companies with responsibility for all global strategic and executional aspects of clinical development.

Ergomed has particular expertise in the clinical development of oncology, immunology and orphan drugs. This along with its Co-Development Business – where Ergomed leverages its expertise and services in return for carried interest in the drugs under development – are areas of focus for the Asian operations. The new team will be backed by the full resources of Ergomed’s extensive worldwide operations currently in over 40 countries.

Dr Sy-Shi Wang, Ergomed’s Executive Director of Global Clinical Operations, said: “Taiwan is a market with tremendous potential and home to some of the world’s most progressive, forward-thinking organisations in biopharma development. I am very excited by the opportunity this presents and the foothold it provides Ergomed to expand further our Asian presence.”

About Ergomed & Forward Looking Statements http://www.ergomedplc.com/ergomed-strengthens-presence-in-asia-to-meet-increasing-demand-for-drug-development-services/

For further information, please contact:
Hume Brophy
Mary Clark, Supriya Mathur and Hollie Vile
Tel: +44(0)203-440-5654
ergomed@humebrophy.com

Stifel Nicolaus Europe Limited
Advisers/Broker to the Company
Jonathan Senior, Giles Balleny
Tel: +44(0)207-710-7600

Marken Announces New Shanghai Office

— Opening Joins the Existing Beijing Office for an Expanded Presence in China

RESEARCH TRIANGLE PARK, North Carolina, March 24, 2015 /PRNewswire/ — Marken announced today the opening of their brand new office in Shanghai, China. The logistics operations center will serve many of Marken’s pharmaceutical clients in Shanghai, Suzhou and surrounding areas.

Logo – http://photos.prnewswire.com/prnh/20110930/NY78064LOGO

The facility is strategically located, as are all of Marken’s branches and depots, to provide regional distribution and supply chain logistics services for pharmaceutical products and medical devices for the clinical trials industry. Located close to both the Hongqiao and Pudong airports, the new office within the Zhangjiang high tech district is also in close proximity to several of Marken’s existing pharma clients. Temperature controlled vehicles will join Marken’s fleet to provide ground transportation for time and temperature sensitive shipments. With Asia now a top clinical trial destination, Marken’s growth in the number of offices, depots and now growing number of full time employees in China is tied to their commitment to provide services and facilities where clients need them to be located. In preparation for this growth, Marken was granted a 12 year license to ship biological samples and drug product within China.

An opening ceremony took place yesterday with Marken’s Chief Executive Officer, Wes Wheeler in attendance, and included many of Marken’s local clients in the area. Wes spoke about the new facility. “We are very proud to welcome the Shanghai team to the global Marken network of offices. These logistical experts bring many years of relevant experience to the organization, and the physical presence of this new office now expands the number of clients Marken can serve within the Asia Pacific region. Our opening of the Shanghai office compliments the existing Beijing office and, combined with a fully certified GDP depot, works together seamlessly to provide complete services to our China-based clients.”

Celebrating 35 years, Marken is the world’s only Clinical Logistics Organization (CLO), providing logistic services to the pharmaceutical, biotechnology, and medical device and life sciences industries.

About Marken 
Marken is the leading global clinical supply chain solutions provider dedicated to the pharmaceutical and life sciences industries, supporting over 49,000 clinical investigators in more than 150 countries. Marken integrates depot and logistics into solutions that extend the reach of clinical trials to even the most remote treatment-naive geographies. Marken is 100% dedicated to the clinical research industry and a specialist in the transportation of investigational medical products and medical devices. In addition to services such as the storage and distribution of clinical trial materials and drug products to investigators or the patients directly, Marken maintains a leading position for the shipment of biological samples and offers additional services such as shipment lane qualifications as well as GDP, regulatory and compliance consultancy.

Galaxy Entertainment Group Reports 2014 Annual Results

Group Adjusted EBITDA up 5% Year-on-Year to $13.2 Billion

Net Profit Attributable to Shareholders Increased by 3% Year-on-Year to $10.3 Billion

Galaxy Macau™ Phase 2 and Broadway at Galaxy Macau Set to Open on Schedule as The Next Major Projects in Macau on 27 May 2015

Subsequently Announced Another Special Dividend of $0.28 Per Share

HONG KONG, March 19, 2015 /PRNewswire/ — Galaxy Entertainment Group Limited (“GEG” or “the Group”) (HKEx stock code: 27) today reported results for the three months and twelve months periods ended 31 December 2014.

FULL YEAR & Q4 2014 HIGHLIGHTS

GEG: Solid Revenue and Earnings Amid Challenging Second Half of 2014

  • Full year Group revenue increased by 9% year-on-year to $71.8 billion
  • Full year Group Adjusted EBITDA of $13.2 billion, an increase of 5% year-on-year
  • Net profit attributable to shareholders grew 3% year-on-year to $10.3 billion
  • Fourth quarter Group Adjusted EBITDA decreased 25% year-on-year to $2.7 billion

Galaxy Macau™: Resilient Performance

  • Full year revenue increased by 18% year-on-year to $46.9 billion and Adjusted EBITDA grew by 12% year-on-year to $9.9 billion
  • Fourth quarter Adjusted EBITDA decreased 19% year-on-year to $2.0 billion
  • StarWorld Macau: Decline in Full Year Revenue and Adjusted EBITDA Due to Worse than Expected Fourth Quarter
  • Full year revenue decreased by 4% year-on-year to $22.6 billion and Adjusted EBITDA of $3.5 billion, a decrease of 6% year-on-year
  • Fourth quarter Adjusted EBITDA of $645 million, a decrease of 38% year-on-year

Development Update: Launch of Galaxy Macau Phase 2 and Broadway at Galaxy Macau

  • Galaxy Macau™ Phase 2 and Broadway at Galaxy Macau — On schedule to open 27 May 2015 as the next major projects in Macau, taking Cotai investment to $43 billion of a total planned $100 billion
  • Cotai Phases 3 & 4 — Site investigation works expected to commence in 2015
  • Hengqin — Plans to develop a world class destination resort on a 2.7 sq.km land parcel moving forward
  • International — Continuously exploring opportunities in overseas markets

Balance Sheet: Remains Well Capitalised and Return of Capital to Shareholders

  • Cash on hand of $9 billion and a net cash position of $8.2 billion, virtually debt free
  • Subsequently announced another special dividend of $0.28 per share payable on or about 22 May 2015

Dr. Lui Che Woo, Chairman of GEG said:

“Marking our ten year anniversary in Macau, GEG achieved solid revenue and EBITDA growth of 9% and 5% respectively, despite facing challenging headwinds in the second half of the year. Our ‘World Class, Asian Heart’ service philosophy is imbedded in all aspects of our business and governs every interaction with the customer, enabling us to deliver spectacular and unique holiday experiences.

“In the ten years since we made our debut in Macau, we have built and established world class, award winning hotels and resorts. Today our commitment to supporting Macau to become a World Centre of Tourism and Leisure is stronger than ever. Two ground breaking projects — Galaxy Macau Phase 2 and the rebranded Broadway at Galaxy Macau — are scheduled to open on 27 May 2015. Doubling our footprint to over one million square metres, they take our investment in Cotai to $43 billion — well on the way to our target of investing $100 billion once Phases 3 & 4 are completed. Furthermore, as a good corporate citizen, we always believe that ‘what is taken from the community is to be used for the good of the community’. We are confident that the recently announced $1.3 billion GEG Foundation will reinforce GEG’s commitment to promoting a sustainable future for Macau and make a meaningful difference to the lives of young people in Macau and on the Mainland.

“In parallel, reflecting our commitment to returning capital to shareholders, we paid two special dividends totalling $4.9 billion in 2014 and subsequently announced another special dividend of $0.28 per share.

“There can be no doubt that the second half of 2014 was one of the most challenging periods in the history of Macau. It is therefore more important than ever that all stakeholders in the industry and Macau pull together in one direction to ensure Macau fulfils its vast economic and social development potential.

“We remain optimistic about the future as the fundamental growth drivers for the market such as increasing domestic consumption in China, a rapidly growing affluent middle class and major planned infrastructure improvements, remain unaltered. Together with our clear roadmap for growth, strong balance sheet and powerful brand, we are confident that we can differentiate ourselves from our peers and attract a greater share of new visitors to Macau.

“As always, I would like to thank our team of 17,000 staff for their tireless effort and contributions to the Group’s success.”

Market Overview

2014 saw two very contrasting half year performances, with total gaming revenue in H1 increasing 13% year-on-year and registering an all-time monthly high in February of $36.9 billion, up 40% year-on-year. However, a confluence of factors such as the FIFA World Cup, China’s soft economic landing, rising costs and the Chinese austerity program etc., weighed on the market in the second half resulting in 3% decline in full year total gaming revenue to $341.3 billion. Encouragingly, visitor numbers to the Macau region grew faster than the previous year, increasing by 8% year-on-year to 31.5 million. Visitors from the Mainland increased at an even faster rate of 14% and now represent 67% of total visitors to Macau (2013: 64%).

Underscoring Macau’s continuing appeal as a vibrant and dynamic tourism and leisure hub catering to a broader customer base, mass revenue increased by 16% year-on-year to $120.9 billion, now accounting for approximately 35% of the Macau market. VIP revenue in the year decreased by 11% year-on-year to $206.3 billion. It remains the largest segment of the market, accounting for approximately 60% of total gaming revenue.

GEG expects the structural shift in the market to mass to continue in the coming years as visitors are drawn to a number of major new projects in Macau that will greatly enhance its MICEE, recreational, dining, retail and entertainment offer, and nearby Hengqin undergoes a transformation into a new regional business and leisure hub. Major planned future infrastructure improvements such as the Taipa Ferry Terminal, the Macau Light Rail Transit and the Hong Kong-Zhuhai-Macau Bridge, are expected to facilitate greater visitor numbers by improving access to Macau and connectivity within the territory. GEG’s complementary properties and Cotai development pipeline leave it well placed to cater for a new type of visitors looking for more holistic holiday and leisure experiences.

Group Financial Results

The Group’s revenue and Adjusted EBITDA for the full year climbed 9% year-on-year to $71.8 billion and by 5% year-on-year to $13.2 billion, respectively, despite a challenging second half of the year. Net profit attributable to shareholders increased 3% year-on-year to $10.3 billion. The results were largely due to Galaxy Macau™ where Adjusted EBITDA grew 12% year-on-year. StarWorld Macau posted a 6% year-on-year decrease in Adjusted EBITDA as challenging market conditions impacted its VIP business in the second half of the year. City Clubs and the Construction Materials Division contributed Adjusted EBITDA of $166 million and $465 million, respectively.

A key contributing factor in the Group’s earnings was the solid performance in the mass segment. Galaxy Macau™’s mass revenue increased from $10.5 billion in 2013 to $12.1 billion in 2014 (up 16%), with StarWorld Macau delivering growth of 12% year-on-year to $4.3 billion. In addition, Galaxy Macau™ also achieved very healthy volume and revenue growth in the VIP segment, with the latter gaining 20% year-on-year to $31.7 billion.

The Group’s total gaming revenue for 2014 on a management basis[1] grew 9% year-on-year to $71.0 billion driven by solid increases in VIP and Mass. Total Mass revenue increased 12% year-on-year to $18.8 billion while VIP revenue climbed 8% year-on-year to $50.4 billion. Electronic gaming revenue also grew 3% year-on-year to $1.8 billion.

Balance Sheet and Special Dividends

The Group’s balance sheet remains well capitalised and liquid, with cash on hand of $9 billion and a net cash position of $8.2 billion as of 31 December 2014. The Group had debt of $790 million. In the year, GEG returned capital to shareholders by paying two special dividends of $0.70 per share and $0.45 per share on 31 July 2014 and 31 October 2014, respectively. Subsequently, the Group has announced another special dividend of $0.28 per share payable on or about 22 May 2015. These dividends reflect management’s confidence in continuing to build out the Group’s development pipeline while generating significant cash flow from operations.

Group Adjusted EBITDA (HK$'m)

Group Adjusted EBITDA (HK$’m)

Galaxy Macau™

Galaxy Macau™ celebrated its third year anniversary in May 2014 and continues to be the growth engine of the Group. The property posted revenue of $46.9 billion, up 18% on the prior year, which translated to a 12% increase in Adjusted EBITDA to $9.9 billion. ROI[2] was 58% for 2014.

Adjusted EBITDA margin under HKFRS and under US GAAP fell by one percentage point year-on-year to 21% and 30%, respectively.

Fourth quarter Adjusted EBITDA was $2.0 billion, a year-on-year reduction of 19%, as market conditions were worse than expected in the second half of the year.

VIP Gaming Performance

Total VIP rolling chip volume for the year was $941.7 billion, up almost 22% on last year. This generated revenue of $31.7 billion (2013: $26.5 billion), an increase of 20% year-on-year. The property closed out the year with fourth quarter VIP net win of $7.4 billion, down 10% year-on-year but up 2% sequentially.

VIP Gaming

HK$’m

Q4 2013

Q3 2014

Q4 2014

QoQ%

YoY%

FY 2013

FY 2014

YoY%

Turnover

236,793

224,435

200,070

-11%

-16%

774,143

941,679

22%

Net Win

8,143

7,239

7,369

2%

-10%

26,491

31,669

20%

Win %

3.4%

3.2%

3.7%

3.4%

3.4%

Mass Gaming Performance

Revenue in the mass segment increased by 16% year-on-year to $12.1 billion (2013: $10.5 billion). Fourth quarter revenue decreased by 8% year-on-year to $2.7 billion.

Mass Gaming

HK$’m

Q4 2013

Q3 2014

Q4 2014

QoQ%

YoY%

FY 2013

FY 2014

YoY%

Table Drop

7,345

6,842

6,363

-7%

-13%

27,896

27,516

-1%

Net Win

2,932

3,070

2,704

-12%

-8%

10,461

12,125

16%

Hold %

39.9%

44.9%

42.5%

37.5%

44.1%

Electronic Gaming Performance

Electronic gaming revenue was $1.6 billion, up 4% on 2013.

Electronic Gaming

HK$’m

Q4 2013

Q3 2014

Q4 2014

QoQ%

YoY%

FY 2013

FY 2014

YoY%

Slots Handle

7,708

9,325

8,515

-9%

10%

30,051

35,581

18%

Net Win

371

419

361

-14%

-3%

1,515

1,576

4%

Hold %

4.8%

4.5%

4.2%

5.0%

4.4%

Non-Gaming Performance

Non-gaming full year revenue increased by 6% year-on-year to $1.5 billion, with fourth quarter revenue climbing 17% year-on-year to $408 million. Hotel occupancy was 98%.

StarWorld Macau

StarWorld Macau generated revenue of $22.6 billion and Adjusted EBITDA of $3.5 billion in 2014, decreases of 4% and 6% year-on-year, respectively. Fourth quarter Adjusted EBITDA decreased 38% year-on-year to $645 million. Strong prior year comparatives and challenging market conditions in the second half of the year were all factors impacting results.

Adjusted EBITDA margin in the year decreased by one percentage point year-on-year to 15% under HKFRS and remained at 25% under US GAAP in 2014. The property generated an ROI[3] of 96% for 2014.

VIP Gaming Performance

StarWorld Macau reported VIP rolling chip volume of $622.8 billion in 2014, down 6% on the previous year. This translated to revenue of $17.8 billion (2013: $19.1 billion). Fourth quarter revenue was lower 29% year-on-year.

VIP Gaming

HK$’m

Q4 2013

Q3 2014

Q4 2014

QoQ%

YoY%

FY 2013

FY 2014

YoY%

Turnover

181,548

150,452

123,628

-18%

-32%

662,022

622,753

-6%

Net Win

4,964

4,412

3,527

-20%

-29%

19,076

17,755

-7%

Win %

2.7%

2.9%

2.9%

2.9%

2.9%

Mass Gaming Performance

Mass gaming revenue for 2014 increased by 12% year-on-year to $4.3 billion (2013: $3.9 billion). Fourth quarter revenue was down 19% year-on-year.

Mass Gaming

HK$’m

Q4 2013

Q3 2014

Q4 2014

QoQ%

YoY%

FY 2013

FY 2014

YoY%

Table Drop

2,935

2,661

2,421

-9%

-18%

11,091

10,890

-2%

Net Win

1,193

1,116

964

-14%

-19%

3,863

4,321

12%

Hold %

40.2%

41.4%

39.8%

34.4%

39.4%

Electronic Gaming Performance

Electronic gaming generated revenue of $181 million, down 13% on last year.

Electronic Gaming

HK$’m

Q4 2013

Q3 2014

Q4 2014

QoQ%

YoY%

FY 2013

FY 2014

YoY%

Slots Handle

781

682

531

-22%

-32%

3,200

2,937

-8%

Net Win

53

45

36

-20%

-32%

209

181

-13%

Hold %

6.8%

6.6%

6.9%

6.5%

6.2%

Non-Gaming Performance

Non-gaming revenue increased by 3% year-on-year to $373 million. Hotel occupancy remained at near capacity throughout the year at 98%.

Developing Macau’s Largest Development Pipeline

Launch of Galaxy Macau™ Phase 2 and Broadway at Galaxy Macau

Ten years after opening its first property in Macau, GEG’s next chapter of growth is scheduled to begin with the official opening of Galaxy Macau™ Phase 2 and the rebranded Broadway at Galaxy Macau on 27 May 2015. They will take GEG’s investment in Cotai to $43 billion and double the existing footprint of the resort to 1.1 million square meters. They will offer an unprecedented selection of amenities and attractions that will deliver a more diverse set of experiences for visitors.

Major highlights include:

  • Six hotels providing approximately 4,000 rooms, suites and villas plus two spas, including The Ritz Carlton’s first All-Suite hotel, The Ritz-Carlton, Macau with over 250 suites; Asia’s largest JW Marriott, JW Marriott Hotel Macau with over 1,000 rooms and Broadway Hotel offering 320 well-appointed rooms, complemented by three existing world class hotels: Banyan Tree Macau, Hotel Okura Macau and Galaxy Hotel
  • The Broadway Theater, comprising 3,000 seats and offering guests a unique up-close-and-personal family-friendly entertainment experience featuring the best of traditional and contemporary Asia culture as well as international shows and performances
  • An expanded Grand Resort Deck complete with Skytop Adventure Rapids, featuring the world’s longest skytop aquatic adventure ride at 575 meters long and the world’s largest skytop wave pool
  • The Broadway — a vibrant street and entertainment district showcasing Macanese culture through hawker-style vendors, live entertainers and world class performers, a first in the territory
  • The Promenade, featuring over 200 luxury and lifestyle retail brands
  • Over 120 food & beverage outlets, offering everything from authentic pan-Asian cuisine to world class dining experiences from Michelin starred chefs
  • Portfolio of unique venues and experiences for meetings, incentives and banquets, catering for up to 3,000 guests

GEG believes the dramatically expanded Galaxy Macau™ and Broadway at Galaxy Macau will set a new benchmark in Asia leisure and tourism, creating unforgettable experiences for the whole family to enjoy.

Cotai Phases 3 & 4

Final plans for Phases 3 and 4 of GEG on Cotai are almost complete and site investigation works are expected to begin in 2015. Once these phases are operational, GEG will have realised its overall target of investing $100 billion in Cotai and will have doubled its footprint in Cotai to 2 million square metres, adding thousands of new hotel rooms to the Group’s portfolio.

Hengqin

In early 2014 GEG entered into a framework agreement for a 2.7 square kilometer land parcel to move forward with the proposed development of a world class, low density leisure and entertainment destination resort on Hengqin. Plans are moving apace and GEG expects the development to be highly complementary to its existing and planned portfolio.

International

GEG continues to actively explore development opportunities in overseas markets.

City Clubs and Construction Materials Division

City Clubs delivered Adjusted EBITDA of $166 million in 2014, a decrease of 8% year-on-year.

Construction Materials Division posted an Adjusted EBITDA of $465 million, down 5% year-on-year.

Community Reinvestment

To mark the Group’s ten year anniversary in Macau and recognising the importance of giving back to the local community and rewarding its 17,000 team members for their valuable contribution to the business, GEG announced two important initiatives in 2014:

  • The announced establishment of a $1.3 billion GEG Foundation in July 2014 which will focus on educating and empowering the young people of Macau and Mainland China.
  • An enhanced employee benefits package which reflects the importance of our team members and the critical role each and every member plays in our continued success.

Both initiatives are consistent with GEG’s commitment to community reinvesting and being a responsible corporate citizen and employer.

Selected Major Awards

Award

Presenter

GEG

Best Managed Companies in Asia – Gaming

Euromoney Magazine

Gaming and Lodging – Best Company

Institutional Investor Magazine – All Asia Executive Team Survey

Casino Operator of the Year Australia / Asia

International Gaming Awards

Best Hotel Group Award

Robb Report China’s 2014 Best of the Best

Forbes Asia’s Fabulous 50 Companies

Forbes Asia Magazine

Galaxy Macau™

Casino VIP Room of the Year

International Gaming Awards

Best Resort of the Year (HK/Macau)

Travel Weekly Magazine and Events Magazine jointly organized – China Travel & Meetings Industry Awards

Best Service Resort Asia

Golden Horse Award of China Hotel

Top 10 Resort Hotels of China

China Hotel Starlight Awards

Hurun Report Best of the Best Awards – Luxury Hotel in Macau Star Performer

Hurun Report

StarWorld Macau

Best Service Hotel of the Year

Travel Weekly Magazine and Events Magazine jointly organized – China Travel & Meetings Industry Awards

Best Service Hotel of Asia

Golden Horse Award of China Hotel

Top 10 Glamorous Hotels of China

China Hotel Starlight Awards

Best Hotel Brand and Service

Exmoo

2014 Asia’s Top Leisure Hotel

NOW Travel Asia Awards

Group Outlook for 2015

GEG is optimistic about the prospects for Macau and the Group in the medium to long term. This confidence is supported by two principal factors: unchanged fundamental drivers for growth such as increasing domestic consumption, a fast growing affluent middle class determined to expand their horizons through travel and planned major infrastructure improvements, all of which will drive visitors to Macau; and secondly, GEG’s substantial and unique development pipeline.

While the market remains challenging, encouragingly visitation to Macau continues to increase. GEG’s hotels are operating at near capacity, highlighting their strong ongoing appeal and robust market demand. Management will continue to focus on driving operational efficiencies, tailoring the offer to meet the evolving market and ensuring the best use of resources. These measures, combined with the opening of Galaxy Macau™ Phase 2 and Broadway at Galaxy Macau in late May, give GEG optimism that growth will resume in the second half of 2015.

Tourism and entertainment is the primary driver of employment creation and economic security for all residents of Macau. All constituents need to harmoniously work together in the current challenging period to ensure that the success that Macau has enjoyed over the past 10 years will continue into the future.

Looking to the future, GEG believes that its strong track record of building world class destination resorts, unique product and service offer and intimate understanding of Asian customers’ changing holiday desires and needs, will translate to sustainable growth in the years ahead.

[1]

The primary difference between statutory revenue and management basis revenue is the treatment of City Clubs revenue where fee income is reported on a statutory basis and gaming revenue is reported on a management basis.

[2]

ROI calculated based on the total Adjusted EBITDA for the latest twelve months divided by gross book value through 31 December 2014 including allocated land cost.

[3]

ROI calculated based on the total Adjusted EBITDA for the latest twelve months divided by gross book value through 31 December 2014 including allocated land cost.

About Galaxy Entertainment Group (HKEx stock code: 27)

Galaxy Entertainment Group Limited (“GEG”) is one of Asia’s leading gaming and entertainment corporations, and is a member of the Hang Seng Index.

GEG primarily develops and operates hotels, gaming and integrated resort facilities in Macau, the only legal gaming location in China and the largest gaming entertainment market in the world.

The two flagship properties of GEG include Galaxy Macau™, a world class integrated destination resort opened in May 2011 at Cotai, and StarWorld Macau, an award-winning property opened in 2006 on the Macau peninsula.

In April 2012, GEG announced the development of Galaxy Macau™ Phase 2 that will nearly double the size of the existing resort to one million square meters. Upon its scheduled opening in May 2015, Galaxy Macau™ Phase 2 will bring to Macau some of the most exciting entertainment, leisure, retail and MICEE facilities. In December 2012, GEG outlined its concept plans for Phases 3 & 4 of its Cotai landbank and expects to commence site investigation works in 2015.

Broadway at Galaxy Macau will be a family oriented integrated resort, linked to Galaxy Macau™ with an air-conditioned sky-bridge.

GEG has entered into a framework agreement with the Hengqin authority to develop a 2.7 square kilometer land parcel for a world class destination resort in Hengqin. This project will complement GEG’s business in Macau and differentiate us from our peers, as well as play a key role in supporting Macau to become a World Center of Tourism and Leisure.

Additionally, GEG operates a Construction Materials Division.

For more information about the Group, please visit www.galaxyentertainment.com.

For Media Enquiries:

Galaxy Entertainment Group – Investor Relations
Mr. Peter J. Caveny / Ms. Yoko Ku / Ms. Winnie Lei
Tel: +852-3150-1111
Email: ir@galaxyentertainment.com

Photo – http://photos.prnasia.com/prnh/20150319/8521501757-b 

Pegasus Signs New Cinema Deal at “Vivo City”, Shanghai

HONG KONG, March 16, 2015 /PRNewswire/ — The Board of Directors of Pegasus Entertainment Holdings Limited (“Pegasus” or the “Company” and its subsidiaries, together the “Group”, stock code: 1326) was pleased to announce on 13 March 2015 that a joint venture company (“JV Company”), which is owned as to 60% by a wholly-owned subsidiary of the Company, entered into a 15-year lease agreement on the same date regarding the leased premises for the Group’s new cinema in Shanghai. This new cinema under the Pegasus brand of “Cinema City” (“Cinema City Shanghai”) will be situated on the top two levels of “Vivo City”, a large-scale retail complex in the CBD district of Minxing in Shanghai, which is developed by the Mapletree Group of Singapore, with construction expected to complete by first quarter of 2016.

As a condition to the lease agreement, the Company’s subsidiary entered into a guarantee of amount not exceeding RMB5.9 million in favour of the landlord (an independent third party), in respect of the due performance of the JV Company of its payment and other obligations under the lease. At the same time, Lander Investment Limited (an independent third party) who is the other 40% partner of the JV Company, executed an indemnity of amount not exceeding RMB2.4 million in favour of the Group, in respect of any damages incurred by the Group arising from the guarantee in proportion to Lander’s shareholding in the JV Company.

“Vivo City” ,according to its corporate website, is a new landmark in Southwest Shanghai with a GFA of 120,000 sqm, featuring over 280 shops and over 2,600 parking lots, and situated next to 7 office towers. The mall is strategically located above two metro lines with excellent connectivity to the Hongqiao airport and near to five densely populated residential communities. The Directors believe that such large scale development will bring a vibrant and diversified customer stream and attract majority of the district’s traffic to the mall which will directly benefit the cinema business.

Building on the success of the Pegasus flagship cinema in Hong Kong — Cinema City Langham Place, the Company plans to replicate the success of such model to its cinemas in the PRC, by equipping Cinema City Shanghai with the most advanced projection and sound systems, including the exclusive viewing technology “4DX” originated from South Korea, in order to bring a new and unprecedented film viewing experience to PRC top-tier cities like Shanghai. Cinema City Shanghai is expected to possess at least 9 screens with approximately 1400 seats.

Cinema City Langham Place, which officially commenced operation in early January 2015 after renovation, is ranked first in terms of box office income among all cinemas in Hong Kong, according to statistics from Hong Kong Box Office System. For 2015 YTD, Cinema City Langham Place has already screened 48 films with box office revenue reaching approximately HK$20 million. According to statistics from China Box Office website (www.cbooo.cn), Cinema City Langham Place will be ranked third when compared with cinemas in the PRC in terms of box office income, from 2 February to 1 March 2015. Given the high-end cinema business model under the brand of “Cinema City” has been proven successful, this will be a stamp of approval for the Group’s development strategy and growth potential in the film exhibition business going forward.

According to statistics from State Administration of Press, Publication, Radio, Film and Television of the PRC, the total box office revenue in China for 2014 reached RMB29.6 billion, recording a 36.2% year-on-year increase, of which Chinese domestic films contributed 54.5%. The total box office revenue in Shanghai amounted to RMB1.5 billion during January to September 2014, ranking fifth among all provinces and cities in the PRC. In view of the PRC film exhibition market currently undergoing a golden phase of development, Pegasus is confident that by strategically capturing the growth potential of its targeted markets, the Group’s revenue base is expected to expand and thereby potentially generate higher returns for its shareholders.

Mr. Wong Pak Ming, Chairman of Pegasus, says, “The Group is optimistic about the future of the film industry in the PRC market. Our new cinema located in the prime area of Shanghai underscores the Group’s commitment to its expansion plan of cinema operations in the PRC. Cinema City Shanghai not only forms part of our Group’s expansion strategy into film exhibition business, but is also a complementary extension of our existing core business of film production by way of providing an additional and direct film distribution channel in the form of cinema operation. The project of Cinema City Shanghai is one of the key long-term development plans of the Company, which signifies that Pegasus has strategically positioned itself into diversified cultural businesses, with an aim to initiate a series of lateral business expansions. We will continue to capture sound business opportunities and strive to establish cinemas in more top-tier cities, so as to further expand our foothold in the PRC.”

About Pegasus Entertainment Holdings Limited

Pegasus Entertainment Holdings Limited, as a diversified cultural business group, is principally engaged in the business of films and television series production, distribution, licensing of film rights, film exhibition and post-production.

About “4DX” technology

4DX is a state-of-the-art technology that advances the movie theater experience through motion chairs equipped with motion simulators and by offering environmental effects such as wind, bubbles and scent, etc. that works in perfect synchronicity with the action on screen. There are approximately 100 4DX theaters in 24 countries worldwide with growing recognition in Hollywood. Cinema City Langham Place is the only movie theater in Hong Kong equipped with 4DX technology as of present.

For further details, please refer to the announcement on HKEX website:

http://www.hkexnews.hk/listedco/listconews/SEHK/2015/0313/LTN20150313899.pdf 

Green Cross Expands Cell Therapy Business in China

YONGIN, South Korea, March 11, 2015 /PRNewswire/ — Green Cross, a South Korean biopharmaceutical company, today announced that it had signed MOU on the 6th of March with the Guizhou provincial government of China for the investment in the cell therapy sector in China.

Under the MOU, the company will build a cell therapy facility in the southwestern Chinese province in order to produce and distribute cell therapy products in China. The provincial government will provide administrative supports and human resources for the new facility.

Green Cross has a robust and growing portfolio of approved and investigational cell therapy projects including T cell, NK cell, dendritic cell and stem cells. Cell therapies are an increasingly significant tool in the treatment of serious diseases. Cell-based therapy industry continued to show promising overall growth and even greater growth expected to follow.

“Our investment reflects the strength of our business and the increasingly important role that cell therapy will play in Green Cross’ future,” said BG Rhee, President of Green Cross Holdings. “Over the last 20 years, Green Cross has maintained a significant manufacturing facility and sales forces for plasma fractionation business in China, and we look forward to building on that legacy through this business expansion.”

The Chinese pharmaceutical market has emerged as a major driver of revenue growth for global pharmaceutical companies, according to a report from McKinsey & Company. The report shows that China’s pharmaceutical market has grown at a rapid 21% compound annual rate over the years. In a recent forecast, China’s pharmaceutical market is projected to continue to grow at around 17% annually and likely to become the second-largest pharmaceutical market by 2020.

About Green Cross

Green Cross provides total healthcare solutions that address the evolving needs of human health. Headquartered in Yongin, South Korea, Green Cross specialises in the development and manufacturing of plasma-derivatives, vaccines and recombinant proteins.

This release includes forward-looking statements concerning the company’s business expansion plan in China. The statements are based on assumptions about many important factors. The company does not undertake to update its forward-looking statements.

Fragrance Du Bois Brings Xerjoff to Southeast Asia for the First Time

SINGAPORE, March 9, 2015 /PRNewswire/ — At its flagship boutique in Singapore’s Fullerton Hotel, Fragrance Du Bois announced the first time arrival in Southeast Asia of the luxurious Italian perfume brand, Xerjoff.

Fragrance Du Bois Flagship Boutique at The Fullerton Hotel, Singapore.

Fragrance Du Bois Flagship Boutique at The Fullerton Hotel, Singapore.

Founded in 2004, the Turin-based perfume house — renowned for its enchanting fragrances, encased in exquisite flacons — is delighted to be expanding its worldwide presence.

“We are thrilled to be in Singapore to showcase our finest and exclusive perfumes under Fragrance Du Bois,” said Sergio Momo, Xerjoff’s Founder and Creative Director. “I believe Fragrance Du Bois shares important principles with Xerjoff in the universe of artistic perfumery. It is extremely important for Xerjoff to be represented by dedicated partners who can introduce and support the philosophy of our brand. Additionally,” he concluded, “Singapore is one of the trendiest fashion capitals in the world, and we believe this will be a gateway for many opportunities in the region.”

“It brings us great pleasure to be the first (and only) fragrance house in Southeast Asia, to host and partner with the world acclaimed Xerjoff,” said Nicola Parker, Brand Director of Fragrance Du Bois. “Singapore is only the first stop. Xerjoff will be available in all our flagship boutiques, outlets and fragrance lounges around the word in the coming weeks. We pride ourselves in giving all our customers a luxury experience in fragrance, each and every time they walk into our boutiques or lounges. This partnership with Xerjoff,” Parker concluded, “will further enhance that experience. We offer nothing but the best in the market in order to make sure that our customers’ personal preferences and expectations are met.”

At the heart of the Xerjoff brand and all of its creations, is a combination of traditional perfumery (dating back hundreds of years), and modern, handcrafted bottles. Sergio Momo’s inspiration is derived from his Italian roots, and his dedication to a time-honoured craft has led to the formulation of some of the most memorable and original fragrances currently on the market. Momo’s empathy and understanding of the natural world has also played a part in the overall aesthetic, with a combination of precious and semi-precious hand cut stones, quartz, Murano glass, wood, brass, bronze, gold and leather, taking roles in the succession of masterpieces.

Also lending some weight to the rare and precious works of art that capture these unforgettable fragrances, are the many years of research and development in the art of perfumery, alongside the collaborations with renowned Italian artists. International and Italian ‘Noses’, painters and sculptors – along with jewellery designers, glassblowers, diamond cutters and wood engravers – work together to distil, blend and package the precious essences created in Grasse (South of France), Spain and Italy.

Xerjoff’s collection – redolent of history and tradition, and inspired by elements and events as diverse as Siberian meteorite showers and the ancient Arabian art of perfumery — is sure to contain a perfume that will excite and stimulate the senses of even the most jaded fragrance aficionado.  

Working along parallel lines with Fragrance Du Bois, Xerjoff has dedicated two superb collections to the mystical and enigmatic Oud oil – both presented in beautifully crafted crystal bottles. Sourced from Laos, Indonesia, Thailand, India and Cambodia, the Oud-inspired creations are capturing the imaginations of fragrance enthusiasts worldwide.

A selection of Xerjoff’s luxury fragrances will be available at the Fragrance Du Bois flagship boutique in Singapore from today.  They will also be available in Du Bois’ second flagship boutique in Kuala Lumpur, Malaysia, within a matter of weeks.

Xerjoff in Southeast Asia is exclusively brought to you by Fragrance Du Bois, and prices start from SGD 225.

Xerjoff is one of several new eminent brands that will be available at Fragrance Du Bois over the next few months. For more updates please go to www.facebook.com/fragrancedubois

Notes to Editors:

For further information, please contact:

Samantha Tham
Marketing Executive
Email: samantha.tham@fragrancedubois.com 
Mobile: +65-9144-0933
Office: +65-6299-4998

Adrian Heng
Group Marketing Director
Email: adrian.heng@fragrancedubois.com 
Mobile: +65-9750-7440
Office: +65-6299-1778

Rosy Ursillo
Email: ursillo@xerjoff.com
Mobile: +39-3663545792
Office: +39-011-31-67-023 / +39-011-197-032-46

About Fragrance Du Bois

Fragrance Du Bois is a niche luxury perfume house working closely with sustainable plantations in Asia, bringing exciting new 100% organic Oud oil based fragrances to exclusive markets worldwide. Sustainably sourcing the finest raw materials across the globe, working with French perfumers to create a full range of products, and also providing bespoke fragrance services, Fragrance Du Bois is personal luxury with a conscience. With exclusive fragrance lounges around the world, in Dubai, Hong Kong, Thailand, Malaysia and Singapore, Fragrance Du Bois creates only the finest experience in bespoke perfumery.

Fragrance Du Bois is known as Parfums Du Bois in France and in non-French speaking markets, as Fragrance Du Bois.

About Xerjoff

XERJOFF is a Turin based Perfume House fully dedicated to luxury fragrance.

XERJOFF is a journey to the most precious realm in the world of luxury fragrances; the place where the magical affinity between the wonders of nature and exquisite Italian craftsmanship is celebrated.

Through years of development, XERJOFF has gained strong alliances with many renowned Italian artists who collaborate closely to create the rare and precious art pieces. International and Italian noses, painters and sculptors, jewellery designers and glassblowers, diamond cutters and wood engravers work in harmony to create the precious scents created in Grasse (South of France), Spain and Italy. The result is a series of unique creations of limited edition availability reserved for only the truest of connoisseurs.

About Asia Plantation Capital

Quick facts:

  • US$ 600 million – combined value of assets owned and under management
  • US$ 53.5 million – turnover in the last financial year
  • US$ 100 million – turnover forecast for current financial year
  • 2,000,000 – Aquilaria trees today, on Agarwood plantations.

Asia Plantation Capital (APC) is the owner and operator of a diverse range of commercial plantation and farming businesses across the Asia-Pacific region and around the world, and is part of the Asia Plantation Capital Group of associated companies. Its focus is on multicultural and diverse plantation projects geared to the domestic and commercial demands of the countries in which it operates. Working closely with, and supporting local communities, is an underlying core principle of the APC business, providing social and cultural support, as well as investment, to move these communities away from deforestation and illegal logging activities, previously seen as a main source of income in some regions of Asia. Established officially in 2008 (although operating privately since 2002) the group now has plantation and agricultural projects on four continents, with operational projects at various stages in Thailand, Malaysia, China, Laos, India, Cambodia, Sri Lanka, Myanmar, Vietnam, North America and Europe.

Promoting the use of sustainable and certified wood is the best way of preventing deforestation, protecting biodiversity, and combatting poverty in the tropical rainforest regions. For the yachting sector (a major user of teak) which strives for excellence and which is already involved in environmental efforts, this is also a way of ensuring that no wood from illegal logging is used.

Xerjoff Casamorati Collection is focused on resurrecting the craftsmanship and old world style of La Fabbrica Di Profumi C. Casamorati, a 19th century haute perfumerie established in Bologne.

Xerjoff Casamorati Collection is focused on resurrecting the craftsmanship and old world style of La Fabbrica Di Profumi C. Casamorati, a 19th century haute perfumerie established in Bologne.

Dedicated entirely to traditional Arab perfume making, Xerjoff's Oud Stars is a prestigious collection of six perfumes created from pure Oud distillation.

Dedicated entirely to traditional Arab perfume making, Xerjoff’s Oud Stars is a prestigious collection of six perfumes created from pure Oud distillation.

Photo – http://photos.prnasia.com/prnh/20150309/8521501474-a
Photo – http://photos.prnasia.com/prnh/20150309/8521501474-b
Photo – http://photos.prnasia.com/prnh/20150309/8521501474-c

Particle Measuring Systems Begins Direct Operations In Taiwan

– Particle Measuring Systems Taiwan becomes a direct provider, brings services local to its customers.

CHU-BEI CITY, March 3, 2015 /PRNewswire/ — Particle Measuring Systems Taiwan (PMS), a Spectris company, today begins direct operations in Taiwan. The company’s acquisition of its trade and assets from Sunway Scientific Corporation (Sunway) demonstrates its growing commitment to serving customers in this region.

PMS will provide customers with onsite calibrations, local support and the opportunity to leverage a global network of dedicated resource personnel who specialize in the microelectronics and highly regulated life sciences industries.

“Particle Measuring Systems is the leading supplier of microcontamination monitoring instrumentation,” said John Hsu, CEO and president of Sunway Scientific Corporation. “After many years of significant contribution to Taiwan’s high-end microelectronics and life sciences industries, we believe customers will benefit from PMS direct operations in Taiwan.”

Direct customer contact will allow PMS to simplify its processes and provide key advantages, such as more responsive service and enhanced customer support. PMS Taiwan can also send professional engineers onsite to develop applications with customers together.

“Sunway has been a dedicated and valued distributor for Particle Measuring Systems, and we feel very fortunate to have worked with them over the years,” said Bill Su, PMS director, Asia Pacific. “With the increasing market opportunities, we feel this direct relationship will continue our focus on giving trusted and inventive products that improve yield loss and processes for our customers.”

By expanding its business in Taiwan, PMS elevates its existing strong presence in the microelectronics industry in original equipment and original design manufacturing.

For more information on PMS Taiwan, visit pmeasuring.com.

About Particle Measuring Systems:

A global technology leader in the environmental monitoring industry, Particle Measuring Systems, a Spectris company, is the inventor of laser particle counting and the largest particle counter manufacturer in the world. Regardless of industry or monitoring requirements, we help manufacturers measure what matters.

Media contacts:
Mice Yen1F-2, No.36, Tai-Yuan St. Chu-Bei City 302
Hsin Chu County, Taiwan, R.O.C.
Tel: +886-3-5525300 Ext: 301
myen@pmeasuring.com  

Sandy Hutchison
5475 Airport Blvd.
Boulder, CO 80301
Tel: +1-303-443-7100
shutchison@pmeasuring.com

Takeda Regroups Singapore Operations in New, Expanded Office

Biopolis Office Signals Increased Focus on Emerging Markets

SINGAPORE and OSAKA, Japan, Feb. 25, 2015 /PRNewswire/ — Takeda Pharmaceutical Company Limited today announced the inauguration of its new office in Biopolis, Singapore. The expanded space will host key Takeda functions  its Emerging Markets Business Unit headquarters, Takeda Development Center Asia and Vaccine Business Unit. Consolidating and streamlining Singapore operations into a centralized office will enhance efficiencies and enable Takeda to better understand and meet the needs of patients and customers in Asia.

As the epicenter of regional Emerging Markets, Singapore’s geographical location and business environment allow Takeda to more easily focus on global clinical development activities, educational initiatives and collaboration with global commercial teams.

Speaking at Takeda’s Inauguration Ceremony today, Dr. Beh Swan Gin, Chairman of the Singapore Economic Development Board, said, “EDB welcomes Takeda’s decision to make Singapore its Emerging Markets Business Unit headquarters.  Singapore has become the preferred location for international companies to locate their regional headquarters in Asia and South East Asia by harnessing our connectivity to the markets around us and our attractive work-live-play-learn environment. But we are not resting on our laurels as we are actively expanding the network and sophistication of professional services firms that support senior decision makers in these regional headquarters.”

Takeda has maintained a presence in Asia-Pacific for more than 50 years, and entered Singapore in 2008. Operations in the region include 1,700 staff in 10 countries. Expansion in Asia is a core component of Takeda’s long-term growth strategies, helping the company to emerge as a top 10 pharmaceutical player in Asia-Pacific.

The new office will house the Takeda Emerging Markets Business Unit, including Asia-Pacific, as well as the Takeda Vaccine Business Unit and the regional Research and Development Center.

“Our patients are the core of what we do at Takeda. Our new space in Singapore will allow us to more quickly address evolving market needs throughout the rapidly growing Emerging Markets, including Asia-Pacific,” said Giles Platford, President, Emerging Markets Business Unit. “It gives us close-to-door access to important market information that will help accelerate the development of medicines needed for battling regional and global health issues.”

Takeda’s decision to relocate the central hub of its Emerging Markets Business Unit demonstrates its dedication to propel the momentum of the Emerging Markets business and the importance of the Asia-Pacific region as a pillar of Takeda’s long-term growth strategy.

The Vaccine Business Unit based in Singapore hosts a laboratory for analytics and development of vaccines to protect against important infectious diseases in the region. One vaccine targets dengue fever and will soon enter phase 3 clinical trials.

Takeda’s Development function is responsible for clinical studies across 12 countries in Asia, supporting clinical activities for compounds in Takeda’s key therapeutic areas.

Asia is a dynamic continent with four billion people across dozens of countries. Many Asian countries are facing the reality of rapidly aging populations and related health issues,” Platford added. “This move in Singapore places us to further strengthen Takeda’s commercial position and clinical development capabilities globally.”

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com .